Trident Diagnostics Limited Liability Company

Trident Diagnostics Limited Liability Company was paid $67K by Medicaid between Jan 2019 and May 2023, across 33 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 53% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#166 of 436

Median peer was paid$17K

This provider vs. median3.9×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	1,215	$23K
2020	362	$25K
2021	602	$16K
2023	2,644	$3K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	53%	659	569	$36K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	5.1%	243	191	$3K
K1034	Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count	3.8%	2,644	2,536	$3K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	3.4%	28	26	$2K
83970		3.2%	55	55	$2K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	3.0%	36	35	$2K
82670		2.2%	55	55	$1K
84402		2.0%	55	55	$1K
84403		2.0%	54	54	$1K
80050	General health panel	1.9%	38	38	$1K
82627		1.7%	55	55	$1K
84270		1.7%	55	55	$1K

21 more codes

83001		1.4%	55	$964.93
83002		1.4%	54	$942.70
82747		1.3%	54	$883.50
84481		1.3%	55	$879.42
82533		1.2%	53	$815.64
82728		1.1%	55	$707.83
84466		<1%	55	$662.59
84144		<1%	30	$592.54
84146		<1%	32	$585.23
84305		<1%	25	$500.50
84439		<1%	55	$468.39
83550		<1%	55	$454.03
83036	Hemoglobin; glycosylated (A1C)	<1%	42	$385.44
84153		<1%	21	$363.72
83735		<1%	53	$334.98
83540		<1%	54	$329.38
86769		<1%	34	$308.12
83003		<1%	17	$266.73
84443	Thyroid stimulating hormone (TSH)	<1%	16	$253.12
83520		<1%	16	$234.08
80053	Comprehensive metabolic panel	<1%	15	$149.25

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFAIZU, SEYED (OWNER)